Wire Stories
-
430PPG divests Traffic Solutions operations in Australia and New Zealand
PITTSBURGH–(BUSINESS WIRE)–PPG (NYSE:PPG) today announced that it has divested all Traffic Solutions operations in Australia and New Zealand to Geveko Markings, a...
-
379Asia Pacific IT, Business Services Spending Down in Q3, ISG Index™ Shows
Managed services ACV fell 13%, while XaaS spending was down 9% in third quarter SYDNEY–(BUSINESS WIRE)–$III #AsaService–After a strong second quarter, demand...
-
494Triton Digital Releases the Australian Podcast Ranker for September 2023
SYDNEY–(BUSINESS WIRE)–Triton Digital®, the global technology and services leader to the digital audio, podcast, and broadcast radio industries, announced today the release...
-
333SSR Mining Announces the Sale of Its Sunrise Lake Exploration Property
DENVER–(BUSINESS WIRE)–SSR Mining Inc. (NASDAQ/TSX: SSRM, ASX: SSR) (“SSR Mining” or the “Company”) announced today that it has entered into a definitive...
-
347Oneview Healthcare and Baxter Announce Connected Care Collaboration During Meeting with Enterprise Ireland
CHICAGO–(BUSINESS WIRE)–Oneview Healthcare (Oneview), a leading provider of patient experience solutions, and Baxter International Inc. (Baxter), a global medtech leader, are pleased...
-
335ClickUp Doubles Down on Investment in APAC with Localised Data Hosting and Regional Hires
ClickUp expands presence in-region to grow impact and better support customers SYDNEY–(BUSINESS WIRE)–ClickUp, the productivity platform that brings work together in one...
-
399Outstaffer Raises $1.5 Million From Leading Australian Venture Capital Investors
This strategic round of funding enabled the self-funded startup to accelerate growth and launch its SaaS Global Workforce Platform. MELBOURNE, Australia–(BUSINESS WIRE)–#AustraliaVCs–Outstaffer,...
-
367BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
First-line tislelizumab plus chemotherapy demonstrated a median overall survival of 15.0 months versus 12.9 months for placebo plus chemotherapy in the intent-to-treat...
-
340BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
Late-breaking ESMO data show 56.2% of patients with resectable NSCLC who received tislelizumab plus chemotherapy before surgery achieved major pathological response, versus...
-
387FaceMe® Ranks First in NIST FATE Test for Presentation Attack Detection (PAD)
TAIPEI, Taiwan–(BUSINESS WIRE)–CyberLink Corp. (5203.TW), a pioneer in AI and facial recognition technologies, has achieved the highest ranking in the Video Convenience...
